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Abstract
Background: Giant cell arteritis (GCA), if untreated, can lead to blindness and stroke. The study’s objectives were to
(1) determine a new evidence-based benchmark of the extent of diagnostic delay for GCA and (2) examine the role
of GCA-specific characteristics on diagnostic delay.
Methods: Medical literature databases were searched from inception to November 2015. Articles were included if
reporting a time-period of diagnostic delay between onset of GCA symptoms and diagnosis. Two reviewers
assessed the quality of the final articles and extracted data from these. Random-effects meta-analysis was used to
pool the mean time-period (95% confidence interval (CI)) between GCA symptom onset and diagnosis, and the
delay observed for GCA-specific characteristics. Heterogeneity was assessed by I2 and by 95% prediction interval (PI).
Results: Of 4128 articles initially identified, 16 provided data for meta-analysis. Mean diagnostic delay was 9.0 weeks
(95% CI, 6.5 to 11.4) between symptom onset and GCA diagnosis (I2 = 96.0%; P < 0.001; 95% PI, 0 to 19.2 weeks).
Patients with a cranial presentation of GCA received a diagnosis after 7.7 (95% CI, 2.7 to 12.8) weeks (I2 = 98.4%;
P < 0.001; 95% PI, 0 to 27.6 weeks) and those with non-cranial GCA after 17.6 (95% CI, 9.7 to 25.5) weeks
(I2 = 96.6%; P < 0.001; 95% PI, 0 to 46.1 weeks).
Conclusions: The mean delay from symptom onset to GCA diagnosis was 9 weeks, or longer when cranial
symptoms were absent. Our research provides an evidence-based benchmark for diagnostic delay of GCA and
supports the need for improved public awareness and fast-track diagnostic pathways.
Keywords: Diagnostic delay, Giant cell arteritis, Meta-analysis, Systematic review
Background
Giant cell arteritis (GCA) is the most common form of
medium and large-vessel vasculitis [1]. Inflammation
typically affects head and neck arteries, including the
superficial temporal and posterior ciliary arteries [2].
Symptoms are caused by local vascular ischaemia often
combined with cytokine-mediated features [3]. Symp-
toms may include headache, jaw claudication, transient
visual loss, scalp tenderness, and limb claudication [4]. If
GCA is untreated, permanent visual loss or stroke may
ensue [5], other potential complications include aortic
aneurysm, dissection and rupture [6].
In the UK, 10 people per 100,000 are reported to be af-
fected by GCA [7], with women being three times more
likely to be affected than men [8]. GCA occurs after age 50
and its incidence increases with age [7, 9], with a strong as-
sociation with polymyalgia rheumatica (PMR). High-dose
glucocorticoids are a highly effective treatment for GCA
[10]. Early diagnosis and treatment are believed to be cru-
cial since visual loss may occur in up to 15–20% of patients
with GCA before treatment is commenced, while visual
loss after the first 1–2 weeks of treatment is very rare [11].
Diagnosis of GCA in primary care remains difficult.
Primary care physicians are faced with the frequently
non-specific nature of many early symptoms of GCA, its
relative rarity and a high prevalence of similar symptoms
in the general consulting population [3, 12]. Delay to
diagnosis is therefore not unusual [13, 14]. Delay may
also occur as patients may not be aware of the
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significance of GCA symptoms, such as jaw claudication
and temporal artery abnormality, and therefore do not
seek healthcare promptly [15].
The importance of understanding the extent of diag-
nostic delay, and the reasons associated with delay, has
been widely investigated by those seeking to improve
care for patients with other conditions, including ischae-
mic heart disease and cancers [16, 17]. This has led to
the development of public health interventions to raise
awareness [18, 19]. For GCA, a secondary care ‘fast-
track’ referral pathway, combined with GP education,
reported a significant reduction in the number of pa-
tients experiencing permanent sight loss compared to
those going through usual care. Though multifactorial,
the reduction in diagnostic delays played a role in
achieving this reduction in sight loss [20].
Our aim was to systematically review the existing lit-
erature reporting the extent of delay in receiving a GCA
diagnosis. Our specific objectives were (1) to determine
a new evidence-based benchmark of the extent of this
delay by pooling the mean time-periods between GCA
symptom onset and diagnosis of GCA and (2) to exam-
ine the role of GCA-specific characteristics on delay.
Methods
A systematic review and meta-analysis of research literature
was conducted. Medical bibliographic databases were
searched to identify articles containing data on the mean
time-period between the onset of GCA symptoms and GCA
diagnosis. Meta-analysis was used to determine a pooled esti-
mate of the time-period of diagnostic delay and analysed
with regards to different GCA-specific characteristics.
Data sources, searches and study selection
The article search was performed using bibliometric data-
bases (MEDLINE, CINAHL, PsycInfo and ISI web of know-
ledge). Article inclusion criteria were (1) a population with
GCA and (2) reporting a time-period of diagnostic delay
between the onset of GCA symptoms and GCA diagnosis
as an outcome. No restrictions were placed on language
and authors were contacted to locate articles where neces-
sary. Diagnosis of GCA could be defined by positive tem-
poral artery biopsy, by American College of Rheumatology
(ACR) 1990 criteria [21], or by a documented clinical diag-
nosis of GCA. Articles were excluded if patients did not
have GCA or did not report diagnostic delay.
From the total number of articles identified through
all searches, a single reviewer (HR) initially screened the
articles by title. Two reviewers (HR & JAP) independ-
ently screened articles by their abstracts and then, upon
consensus, the remaining articles were reviewed in full
(JAP & CDM). Finally, the reference list of each included
article was checked for further relevant articles by a sin-
gle reviewer (JAP).
Data extraction
Data were extracted from eligible articles by two re-
viewers (JAP & TH). The primary outcome of interest
extracted from the final included articles was the mean
time-period between onset of GCA symptoms and GCA
diagnosis and the related estimate of variance. Other
data extracted included lead author name, publication
year, time-period between which patients were recruited
or sampled from medical records, sample size, sex, age,
country, healthcare setting, GCA-specific characteristic,
method of GCA diagnosis, and how a delay in diagnosis
had been defined. GCA-specific characteristics were ex-
amined within three categories, namely (1) commonly-
reported GCA symptoms (polymyalgic symptoms, visual
manifestation, visual loss, headache, jaw claudication
and scalp tenderness); (2) subtype of GCA (cranial or
non-cranial, presence or absence of PMR, positive or
negative biopsy result); and (3) sample demographic
(age, geographical location and sex).
Quality assessment
Two reviewers (JAP & TH) assessed the quality of the
final articles using a modified version of the Newcastle-
Ottawa quality assessment scale for cohort studies.
Though articles could be cross-sectional, case–control
or cohort in design, several criteria were chosen from
the cohort version of the Newcastle-Ottawa tool as this
best represented the qualities required.
Data synthesis
The primary outcome of interest was the mean number
of weeks between symptom onset and GCA diagnosis,
with an accompanying estimate of variation (standard
deviation (SD)); however, several articles reported data
in other formats. Where possible, the corresponding au-
thor was contacted and data requested in the required
format. Where data were not provided, data were con-
verted to allow direct comparisons between datasets.
Data conversion could occur in three instances, depend-
ing on the originally reported format. Firstly, if delay was
reported in days or months, these values were converted
to weeks. Secondly, if an article had reported the vari-
ance around a mean using a low to high range, then this
was converted to a SD (using a formula from Hozo et al.
[22], low to high range data was used to generate an im-
puted SD [23]). Thirdly, the SD for each dataset was
converted to a standard error (SD/√n) for use in the
meta-analysis.
Analysis
All articles included in the systematic review were ini-
tially examined using a narrative synthesis, comparing
the characteristics of these articles. Random-effects
meta-analysis was used to report a pooled mean number
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of weeks (95% confidence interval (CI)) between symp-
tom onset and GCA diagnosis. This meta-analysis was
presented as a forest plot, with heterogeneity initially
assessed using the I2 statistic and then using 95% predic-
tion intervals (PI) as advocated by Riley et al. [24]; 95%
PIs may be added to summary results from random-
effects meta-analyses to illustrate heterogeneity of effects
that may not be fully conveyed by the 95% CI. Where
there is a wide distribution of effect estimates with little
overlap in confidence intervals, 95% PI can highlight a
range of effects at the individual level across study set-
tings and can prove more useful in clinical practice than
a summary I2 value.
Because the SD required imputation for several arti-
cles, sensitivity analyses were performed, firstly examin-
ing only those articles which originally reported SD,
secondly only those articles which required imputation
of SD, and thirdly those restricting GCA definition to
biopsy-positive cases only. Finally, the extent of delay re-
lating to GCA-specific characteristics was reported, with
random-effects meta-analysis being conducted where
there were a sufficient number of articles to do so.
Results
Search results
Out of 4128 articles initially identified, 141 were
reviewed in full, leaving a total of 23 articles for inclu-
sion. Of these, 11 were subsequently excluded as their
datasets were duplicates of other articles. A further 10
additional articles were identified from reference lists.
Therefore, 22 articles were included in the systematic re-
view [11, 13, 20, 25–43], with 16 of these being pooled
through meta-analysis [11, 13, 20, 26, 28, 30–33, 36, 37,
39–43]. From these 16 articles, 9 included GCA-specific
characteristic data [11, 13, 28, 30–32, 37, 41, 43] and,
when a further 6 previously excluded articles were rein-
troduced (articles using the same datasets now used in
separate analyses), this totalled 15. Finally, 6 of these ar-
ticles were included in the GCA-specific characteristic
meta-analysis [11, 13, 28, 31, 41, 44] (Fig. 1).
Sample characteristics
Of the 22 articles included in the systematic review, 10
came from England or the US. Two articles included pa-
tients from primary care and 16 had a retrospective
study design. The 22 articles comprised 2474 GCA pa-
tients, of whom 72% were female and the average age
was 73 years (mean ages ranging from 63–79, excluding
the outlier of Hu et al. [34], which was removed due to a
far younger mean age (43 years) and predominantly male
sample (15:1 ratio of males to females)). A total of 17 ar-
ticles defined GCA by a positive temporal artery biopsy,
with the remainder using clinical diagnosis or ACR cri-
teria. None of the included articles had examined
diagnostic delay of GCA as their primary question; there
was little information on how delay data was collected
(Table 1).
Diagnostic delay of GCA
The mean delay in receiving a diagnosis of GCA ranged
from 1.2 (SD 1.6) to 34.7 (34.2) weeks. The majority of
mean values had wide data ranges reported alongside
them, with these often being skewed toward the higher
value (Table 2). Five articles did not include all necessary
data related to delay [25, 27, 29, 35, 38] and that of Hu
et al. [34] was excluded (Additional file 1: Table S1),
leaving 16 articles included in the meta-analysis [11, 13,
20, 26, 28, 30–33, 36, 37, 39–43].
The pooled mean time between GCA symptom onset
and GCA diagnosis was 9.0 weeks (95% CI, 6.5 to 11.4)
(I2 = 96.0%, P < 0.001) (Fig. 2). Sensitivity analysis showed
minimal difference in the length of delay if only articles
that reported the original SD (8.7 (5.1 to 12.3) weeks,
I2 = 97.5%, P ≤ 0.001) (Additional file 1: Figure S1), im-
puted SD (9.1 (6.6 to 11.6) weeks, I2 = 84.6%, P ≤ 0.001)
(Additional file 1: Figure S2), or those that had defined
GCA through temporal artery biopsy (8.6 (5.6 to 11.5)
weeks, I2 = 96.7%; P ≤ 0.001) (Additional file 1: Figure S3)
were included.
GCA-specific characteristic diagnostic delay
Nine articles included in the original meta-analysis also re-
ported diagnostic delay for a particular GCA characteristic
(Table 3). Six further articles [44–49] were reintroduced,
their examination of GCA-specific characteristics meaning
they could subsequently be compared against different
datasets (Additional file 1: Table S2).
Five articles had specifically compared diagnostic delay
for those with cranial versus non-cranial GCA. Cranial
GCA was defined as presentation with cranial features
(e.g. headache, scalp tenderness) or positive temporal ar-
tery biopsy. Non-cranial delay was defined as presenta-
tion of GCA with constitutional symptoms (e.g. fever,
anorexia or polymyalgia) or other non-cranial presenta-
tion. Each included article had originally reported a sig-
nificantly greater delay in those with non-cranial GCA
compared with cranial GCA. Our meta-analysis demon-
strated that those with cranial GCA received a diagnosis
after 7.7 weeks (2.7 to 12.8, I2 = 98.4%, P < 0.001) and
those with non-cranial GCA after 17.6 weeks (9.7 to
25.5, I2 = 96.6%, P < 0.001) (Fig. 3).
No other characteristic had been reported often
enough, included an appropriate comparator group or
were from a unique dataset to allow further meta-
analysis. However, within the original articles, signifi-
cantly greater periods of delay had been reported in
GCA patients without symptoms of headache compared
to those with headache (16.6 vs. 9.2 weeks respectively,
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P ≤ 0.001) [44], for those with GCA and PMR compared
to GCA only (13.4 vs. 8.3 weeks, P ≤ 0.001) [44], and for
patients aged ≤ 69 years compared to those aged ≥ 70
(13.2 vs. 9.4 weeks, P = 0.03) [49].
Additionally, 95% PIs were calculated for each meta-
analysis demonstrating an interval of 0 to 19.2 weeks for
the mean time between symptom onset and GCA diag-
nosis (Fig. 2), 0 to 21.8 weeks for articles which reported
SD only (Additional file 1: Figure S1), 1.0 to 17.2 weeks
for those with imputed SD (Additional file 1: Figure S2),
0 to 20.2 weeks for articles where GCA had been defined
through temporal artery biopsy (Additional file 1: Figure
S3), 0 to 27.6 weeks for those with cranial symptoms
(Fig. 3), and 0 to 46.1 weeks for those with non-cranial
symptoms (Fig. 3).
Quality appraisal
All articles included in the systematic review described
samples broadly representative of GCA, based on age
and sex distribution (except for Schmidt et al. [46]) and
had ascertained the method of GCA diagnosis (typically
temporal artery biopsy) from medical records (except for
Pease et al. [37]). The majority of articles determined the
time-period of diagnostic delay through review of med-
ical records, as use of a retrospective cohort design was
typical (Additional file 1: Table S3). Articles included in
Fig. 1 Selection of articles for inclusion in systematic review and meta-analysis
Prior et al. BMC Medicine  (2017) 15:120 Page 4 of 12
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
ar
tic
le
s
re
po
rt
in
g
de
la
y
of
gi
an
t
ce
ll
ar
te
rit
is
(G
C
A
)
di
ag
no
si
s
Le
ad
au
th
or
,r
ef
er
en
ce
Ye
ar
Sa
m
pl
in
g
pe
rio
d
C
ou
nt
ry
H
ea
lth
ca
re
se
tt
in
g
St
ud
y
de
si
gn
D
ef
in
iti
on
of
de
la
y
in
G
CA
di
ag
no
si
s
Sy
st
em
at
ic
re
vi
ew
(n
=
22
)
C
al
am
ia
[2
5]
19
81
19
76
–1
97
8
U
SA
Te
rt
ia
ry
ca
re
Re
tr
os
pe
ct
iv
e
D
ur
at
io
n
sy
m
pt
om
s
w
er
e
pr
es
en
t
be
fo
re
di
ag
no
si
s
Be
lla
C
ue
to
a
[2
6]
19
85
19
68
–1
98
3
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
ur
at
io
n
of
sy
m
pt
om
s
un
til
di
ag
no
si
s
Ka
ra
nj
ia
[2
7]
19
89
–
U
SA
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
A
ve
ra
ge
de
la
y
fro
m
on
se
t
of
sy
m
pt
om
to
bi
op
sy
D
es
m
et
a
[2
8]
19
90
19
82
–1
98
8
Be
lg
iu
m
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Ti
m
e
de
la
y
be
tw
ee
n
pr
es
en
ta
tio
n
an
d
bi
op
sy
Ke
lk
el
[2
9]
19
91
19
84
–1
99
0
Sw
itz
er
la
nd
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Fr
om
fir
st
si
gn
s
or
sy
m
pt
om
s
to
be
gi
nn
in
g
of
tr
ea
tm
en
t
M
yk
le
bu
st
a
[3
0]
19
96
19
87
–1
99
4
N
or
w
ay
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
D
el
ay
of
di
ag
no
si
s
Br
ac
ka
[3
1]
19
99
19
60
–1
99
6
U
SA
Te
rt
ia
ry
ca
re
Re
tr
os
pe
ct
iv
e
Ti
m
e
to
di
ag
no
si
s
D
uh
au
ta
[3
2]
19
99
19
91
–1
99
7
Fr
an
ce
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
Ti
m
e
in
te
rv
al
be
tw
ee
n
on
se
t
of
sy
m
pt
om
s
an
d
di
ag
no
si
s
N
es
he
ra
[3
3]
19
99
19
80
–1
99
5
Is
ra
el
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Ti
m
e
fro
m
on
se
t
of
sy
m
pt
om
s
to
di
ag
no
si
s
H
u
[3
4]
20
02
19
99
–2
00
1
C
hi
na
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
D
ur
at
io
n
of
sy
m
pt
om
s
be
fo
re
bi
op
sy
Li
oz
on
a
[1
1]
20
03
19
77
–2
00
2
Fr
an
ce
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
in
di
ag
no
si
s
N
ue
nn
in
gh
of
f
[3
5]
20
03
19
50
–1
99
9
U
SA
Pr
im
ar
y
&
se
co
nd
ar
y
Re
tr
os
pe
ct
iv
e
Ti
m
e
fro
m
on
se
t
of
sy
m
pt
om
s
to
G
C
A
di
ag
no
si
s
G
on
za
le
z-
G
ay
a
[3
6]
20
04
19
81
–2
00
1
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
Pe
as
ea
[3
7]
20
05
–
En
gl
an
d
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
Ti
m
e
to
pr
es
en
ta
tio
n
Lo
dd
en
ke
m
pe
r
[3
8]
20
07
–
En
gl
an
d
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
O
ns
et
of
sy
m
pt
om
s
pr
io
r
to
ad
m
is
si
on
M
ar
ia
[3
9]
20
09
19
89
–2
00
7
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
in
di
ag
no
si
s
Ez
eo
ny
ej
ia
[1
3]
20
11
20
03
–2
00
8
En
gl
an
d
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Sy
m
pt
om
s
on
se
t
to
di
ag
no
si
s
M
ac
ki
ea
[4
0]
20
11
20
05
–2
00
9
En
gl
an
d
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Ti
m
e
be
tw
ee
n
fir
st
on
se
t
of
sy
m
pt
om
s
an
d
fir
st
st
er
oi
d
tr
ea
tm
en
t
C
zi
ha
la
[4
1]
20
12
20
02
–2
01
0
G
er
m
an
y
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
Ti
m
e
to
di
ag
no
si
s
Pr
ie
to
-G
on
za
le
za
[4
2]
20
12
20
06
–2
01
1
Sp
ai
n
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
D
ur
at
io
n
of
sy
m
pt
om
s
un
til
di
ag
no
si
s
Pa
til
a
[2
0]
20
15
20
09
–2
01
3
En
gl
an
d
Se
co
nd
ar
y
ca
re
Pr
os
pe
ct
iv
e
D
ur
at
io
n
of
sy
m
pt
om
un
til
di
ag
no
si
s
Si
ng
ha
[4
3]
20
15
19
50
–2
00
4
U
SA
Pr
im
ar
y
&
se
co
nd
ar
y
Re
tr
os
pe
ct
iv
e
D
ur
at
io
n
of
sy
m
pt
om
s
In
iti
al
ly
ex
cl
ud
ed
ar
tic
le
s,
su
bs
eq
ue
nt
ly
us
ed
fo
r
ch
ar
ac
te
ris
tic
-s
pe
ci
fic
an
al
ys
is
on
ly
(n
=
6)
G
on
za
le
z-
G
ay
b
[4
5]
20
00
19
81
–1
99
8
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
Sc
hm
id
tb
[4
6]
20
00
19
96
–1
99
9
G
er
m
an
y
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
in
th
er
ap
y
G
on
za
le
z-
G
ay
[4
7]
20
01
19
81
–1
99
8
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
G
on
za
le
z-
G
ay
[4
8]
20
03
19
81
–2
00
1
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
G
on
za
le
z-
G
ay
b
[4
4]
20
05
19
81
–2
00
4
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
Lo
pe
z-
D
ia
z
[4
9]
20
08
19
81
–2
00
6
Sp
ai
n
Se
co
nd
ar
y
ca
re
Re
tr
os
pe
ct
iv
e
D
el
ay
to
di
ag
no
si
s
a I
nc
lu
de
d
in
de
la
y
m
et
a-
an
al
ys
es
b
In
cl
ud
ed
in
ch
ar
ac
te
ris
tic
-s
pe
ci
fic
de
la
y
m
et
a-
an
al
ys
is
Prior et al. BMC Medicine  (2017) 15:120 Page 5 of 12
Ta
b
le
2
Ex
te
nt
of
di
ag
no
st
ic
de
la
y
re
po
rt
ed
w
ith
in
ar
tic
le
s
in
cl
ud
ed
in
sy
st
em
at
ic
re
vi
ew
(n
=
22
)
Se
x
A
ge
Re
po
rt
ed
di
ag
no
st
ic
de
la
y
C
on
ve
rt
ed
di
ag
no
st
ic
de
la
ya
Le
ad
au
th
or
,r
ef
er
en
ce
D
ef
in
iti
on
of
G
CA
n
%
F
M
ea
n
SD
Ra
ng
e
Ti
m
e
M
ea
n
SD
Ra
ng
e
M
ea
n
w
ee
ks
of
de
la
y
SD
C
al
am
ia
[2
5]
Po
si
tiv
e
TA
B
fo
r
G
C
A
af
te
r
fe
ve
r
w
as
in
iti
al
sy
m
pt
om
15
66
.7
67
–
57
–7
5
M
3b
–
–
–
–
Be
lla
C
ue
to
[2
6]
Po
si
tiv
e
TA
B
fo
r
G
C
A
c
10
0
53
71
.6
–
52
–8
8
D
12
6
–
6–
21
90
18
52
Ka
ra
nj
ia
[2
7]
Po
si
tiv
e
TA
B
fo
r
G
C
A
an
d/
or
st
ud
y
de
fin
ed
cl
in
ic
al
cr
ite
ria
63
–
–
–
–
D
52
–
–
–
–
D
es
m
et
[2
8]
Po
si
tiv
e
TA
B
fo
r
G
C
A
34
73
.5
70
.8
–
60
–9
9
–
–
–
–
–
–
Po
si
tiv
e
TA
B
fo
r
G
C
A
,w
ith
cr
an
ia
lo
r
po
ly
m
ya
lg
ia
sy
m
pt
om
sc
21
–
–
–
–
D
8.
5
10
.9
1–
40
1.
2
1.
6
Po
si
tiv
e
TA
B
fo
r
G
C
A
w
ith
co
ns
tit
ut
io
na
l(
fe
ve
r,
fa
tig
ue
,a
no
re
xi
a
or
w
ei
gh
t
lo
ss
)
sy
m
pt
om
s
13
–
–
–
–
D
21
.5
27
.9
2–
10
5
3.
1
4.
0
Ke
lk
el
[2
9]
Po
si
tiv
e
TA
B
fo
r
G
C
A
an
d/
or
st
ud
y
de
fin
ed
cl
in
ic
al
cr
ite
ria
13
0
74
.6
76
7.
5
60
–9
2
M
5b
–
0.
5–
48
–
–
M
yk
le
bu
st
[3
0]
Po
si
tiv
e
TA
B
fo
r
G
C
A
,w
ith
ou
t
PM
Rc
39
–
70
.4
–
–
M
1.
5
–
0.
25
–7
.0
6.
4
7.
2
Po
si
tiv
e
TA
B
fo
r
G
C
A
,w
ith
PM
R
15
–
74
.4
–
–
M
1.
9
–
0.
5–
5
8.
1
10
.7
Br
ac
k
[3
1]
La
rg
e-
ve
ss
el
G
C
A
(G
C
A
di
ag
no
si
s
w
ith
va
sc
ul
iti
c
in
vo
lv
em
en
t)
74
88
66
–
52
–8
5
M
8.
1
–
0.
1–
48
.0
34
.7
34
.2
C
ra
ni
al
G
C
A
(P
os
iti
ve
TA
B)
c
74
78
72
–
54
–8
9
M
2.
6
–
0.
5–
11
.0
11
.1
7.
5
D
uh
au
t
[3
2]
In
ci
de
nt
ca
se
s
of
G
C
A
,w
ho
sa
tis
fy
in
cl
us
io
n
cr
ite
ria
,i
nc
lu
di
ng
po
si
tiv
e
TA
Bc
20
7
75
.8
75
.6
(F
)
74
.1
(M
)
8
7.
4
–
–
D
48
–
5–
21
13
6.
9
50
.2
In
ci
de
nt
ca
se
s
of
G
C
A
,w
ho
sa
tis
fy
in
cl
us
io
n
cr
ite
ria
,w
ith
ne
ga
tiv
e
TA
B
85
65
.9
75
.1
(F
)
74
.0
(M
)
7.
8
8.
6
–
–
D
33
–
4
–
10
96
4.
7
26
.0
N
es
he
r
[3
3]
G
C
A
de
fin
ed
us
in
g
19
90
A
C
R
cr
ite
ria
c
14
4
64
.6
73
.0
–
–
M
1.
5
–
0.
1–
12
6.
4
7.
9
H
u
[3
4]
Po
si
tiv
e
TA
B
fo
r
G
C
A
or
on
cl
in
ic
al
gr
ou
nd
s
(re
sp
on
se
to
st
er
oi
ds
)
16
6.
3
43
.1
–
28
–6
0
M
5.
5
–
0.
25
–2
4.
3
–
–
Li
oz
on
[1
1]
Po
si
tiv
e
TA
B
fo
r
G
C
A
c
17
5
64
.6
75
.2
7.
1
–
D
79
83
.5
–
11
.3
11
.9
Si
le
nt
G
C
A
(c
on
st
itu
tio
na
ls
ym
pt
om
s,
ra
is
ed
er
yt
hr
oc
yt
e
se
di
m
en
ta
tio
n
ra
te
)
21
66
.7
74
.3
7.
9
–
D
12
3
–
30
–
36
0
17
.6
7.
9
O
ve
rt
cr
an
ia
lG
CA
13
0
63
.8
75
.6
6.
9
–
D
70
–
4
–
35
0
10
.0
8.
2
N
ue
nn
in
gh
of
f
[3
5]
G
C
A
de
fin
ed
us
in
g
19
90
A
C
R
cr
ite
ria
16
8
79
.2
75
.6
–
–
D
40
b
–
21
–8
9
–
–
G
on
za
le
z-
G
ay
[3
6]
Po
si
tiv
e
TA
B
fo
r
G
C
A
,w
ith
va
sc
ul
ar
in
vo
lv
em
en
tc
19
9
52
.8
74
.6
7.
0
–
W
9.
8
10
.8
–
9.
8
10
.8
Po
si
tiv
e
TA
B
fo
r
G
C
A
,w
ith
ou
t
va
sc
ul
ar
in
vo
lv
em
en
t
11
72
.7
73
.8
5.
3
–
W
20
.2
17
.6
–
20
.2
17
.6
Pe
as
e
[3
7]
G
C
A
di
ag
no
si
s
(1
99
0
A
C
R
cr
ite
ria
)
af
te
r
in
iti
al
pr
es
en
ta
tio
n
w
ith
po
ly
m
ya
lg
ia
sy
m
pt
om
sc
42
–
71
–
60
–8
1
M
3.
0
–
0.
4
–
22
.1
12
.9
23
.3
Lo
dd
en
ke
m
pe
r
[3
8]
Po
si
tiv
e
TA
B
fo
r
G
C
A
90
74
.4
74
.6
7.
8
–
D
12
5b
–
2–
25
55
–
–
M
ar
i[
39
]
Po
si
tiv
e
TA
B
fo
r
G
C
A
an
d
3
or
m
or
e
19
90
A
C
R
cr
ite
ria
c
79
77
.2
74
.8
–
59
–8
9
D
92
–
12
–
49
8
13
.1
11
.6
Ez
eo
ny
ej
i[
13
]
G
C
A
in
m
ed
ic
al
re
co
rd
sc
65
72
.3
75
D
35
–
2
–
33
6
5.
0
11
.9
M
ac
ki
e
[4
0]
G
C
A
w
ith
is
ch
ae
m
ic
m
an
ife
st
at
io
n
(G
C
A
de
fin
ed
by
19
90
A
C
R
cr
ite
ria
,p
os
iti
ve
TA
B
or
cl
in
ic
al
fe
at
ur
es
)c
22
2
71
.0
72
–
67
–7
8
D
64
98
.3
12
.3
–7
8.
5
9.
1
14
.0
C
zi
ha
l[
41
]
G
C
A
in
m
ed
ic
al
re
co
rd
sc
11
0
76
.4
69
8.
4
–
W
18
.2
21
.8
–
18
.2
21
.8
Ex
tr
a-
cr
an
ia
lG
CA
59
83
.1
62
.5
7.
6
–
W
28
.7
25
.1
–
28
.7
25
.1
Prior et al. BMC Medicine  (2017) 15:120 Page 6 of 12
Ta
b
le
2
Ex
te
nt
of
di
ag
no
st
ic
de
la
y
re
po
rt
ed
w
ith
in
ar
tic
le
s
in
cl
ud
ed
in
sy
st
em
at
ic
re
vi
ew
(n
=
22
)
(C
on
tin
ue
d)
C
ra
ni
al
G
C
A
51
68
.6
73
.7
7.
0
–
W
6.
5
6.
6
–
6.
5
6.
6
Pr
ie
to
-G
on
za
le
z
[4
2]
Po
si
tiv
e
TA
B
fo
r
ne
w
ly
-d
ia
gn
os
ed
G
C
A
an
d
19
90
A
C
R
cl
as
si
fic
at
io
nc
40
67
.5
79
.0
–
57
–9
2
D
74
.2
90
.5
5
–
36
5
10
.6
12
.9
Pa
til
[2
0]
C
on
ve
nt
io
na
lp
at
hw
ay
–
G
C
A
di
ag
no
si
s
in
m
ed
ic
al
re
co
rd
sc
46
71
.7
75
.4
7.
6
–
D
32
.0
39
.5
1–
19
6
4.
6
5.
6
Fa
st
-t
ra
ck
pa
th
w
ay
–
G
CA
ba
se
d
on
cl
in
ic
al
fe
at
ur
es
,l
ab
re
su
lts
,
bi
op
sy
an
d
re
sp
on
se
to
st
er
oi
ds
67
77
.6
74
.1
7.
6
–
D
35
.9
47
.6
0–
20
6
5.
1
6.
8
G
C
A
pa
tie
nt
s
(t
ot
al
)c
20
4
79
.9
76
.0
8.
2
–
D
41
.3
95
.5
–
5.
9
13
.6
Si
ng
h
[4
3]
G
C
A
w
ith
ou
t
vi
su
al
m
an
ife
st
at
io
n.
Po
si
tiv
e
TA
B
fo
r
ne
w
ly
-d
ia
gn
os
ed
G
C
A
an
d
19
90
A
C
R
cl
as
si
fic
at
io
n
15
7
81
.0
75
.6
7.
8
–
D
44
.5
10
7.
3
–
6.
4
15
.3
G
C
A
w
ith
vi
su
al
m
an
ife
st
at
io
n.
Po
si
tiv
e
TA
B
fo
r
ne
w
ly
-d
ia
gn
os
ed
G
C
A
an
d
19
90
A
C
R
cl
as
si
fic
at
io
n
47
77
.0
77
.4
9.
2
–
D
30
.6
31
.1
–
4.
4
4.
4
a I
f
th
e
ex
te
nt
of
di
ag
no
st
ic
de
la
y
w
as
re
po
rt
ed
as
‘d
ay
s’
or
‘m
on
th
s’,
th
is
w
as
co
nv
er
te
d
to
w
ee
ks
b
M
ed
ia
n
c D
at
as
et
us
ed
in
m
et
a-
an
al
ys
is
A
CR
A
m
er
ic
an
C
ol
le
ge
of
Rh
eu
m
at
ol
og
y,
G
CA
gi
an
t
ce
ll
ar
te
rit
is
,T
A
B
te
m
po
ra
la
rt
er
y
bi
op
sy
,P
M
R
po
ly
m
ya
lg
ia
rh
eu
m
at
ic
a
Ti
m
e:
D
da
ys
,W
w
ee
ks
,M
m
on
th
s
Prior et al. BMC Medicine  (2017) 15:120 Page 7 of 12
this review reported good quality of design, though little
indication was provided on how delay was actually
defined.
Discussion
This systematic review and meta-analysis examined the
extent of delay between first experiencing symptoms re-
lated to GCA and receiving a confirmatory GCA diagno-
sis, finding the mean time-period of diagnostic delay to
be 9 weeks. Also of interest was how diagnostic delay is
influenced by GCA-specific characteristics. Here, we
found that even when patients present with distinct cra-
nial symptoms, the delay in finally receiving a GCA
diagnosis remains substantial (8 weeks) and is longer
still for those with non-cranial symptoms (18 weeks).
Such findings are of concern, as previous research has
reported that as few as half of GCA patients can experi-
ence temporal headaches [3].
Achieving a prompt and accurate diagnosis of GCA
remains challenging, demonstrated by typically wide and
skewed time-periods of delay within individual studies.
It was not uncommon for time-periods of delay to range
from a single day in one patient, to a year in another
from the same study. Further research is needed to fully
describe the characteristics of patients experiencing both
short and long periods of delay. When a patient presents
to the clinician with mainly constitutional symptoms,
such as fever or malaise, diagnosis is more challenging
as these symptoms are common and frequently occur in
other, more prevalent disorders. However, patients who
present with classic cranial GCA or typically associated
symptoms (e.g. headache, PMR) still experience a pro-
longed period of diagnostic delay, highlighting the need
for an increased awareness of all facets of this condition.
Diagnostic delay is a common problem in many condi-
tions. For example, a median 9-week delay has been
identified in diagnosing childhood brain tumours [50],
and a 24-week median delay in rheumatoid arthritis
(RA) [51]. As the delay in receiving a diagnosis for such
conditions has been shown to have negative effects on
outcomes, much research has looked to reduce this re-
spective diagnostic delay. It remains unclear at what
point(s) in the patient pathway the greatest potentially
avoidable delay is incurred [52]. Raza et al. [51] exam-
ined the reasons for delay in assessment of RA across
Europe. They found that delays in receiving a RA diag-
nosis could be related to the time taken for (1) the pa-
tient to consult healthcare after symptom onset, (2) the
patient to be given an appointment, (3) the primary care
clinician to refer the patients to secondary care, and (4)
the patient to receive a secondary care appointment; the
extent of delay at each point varied across countries.
Fig. 2 Meta-analysis of time-periods of delay in receiving a diagnosis of giant cell arteritis
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Table 3 Delay of giant cell arteritis (GCA) diagnosis by GCA-specific characteristic
Mean delay by category
Characteristics Author Year n Weeks (SD) n Weeks (SD) P valuea
Symptoms
PMR With Without
Pease [37] 2005 42 12.9 (23.3) – – –
Ezeonyeji [13] 2011 14 6.0 (1.8) – – –
Visual manifestation With Without
Gonzalez-Gay [45] 2000 42 9.6 (11.3) 119 11.5 (12.5) 0.19
Ezeonyeji [13] 2011 23 3.0 (2.9) – – –
Singh [43] 2015 47 4.4 (4.4) 157 6.4 (15.3) –
Visual loss With Without
Gonzalez-Gay [45] 2000 24 10.8 (13.6) 137 11.0 (12.1) 0.48
Schmidt [46] 2000 5 7 (3) – – –
Ezeonyeji [13] 2011 16 1.7 (1.4) – – –
Headache Yes No
Gonzalez-Gay [44] 2005 203 9.2 (9.9) 37 16.6 (15.0) <0.001
Ezeonyeji [13] 2011 54 4.3 (3.9) – – –
Jaw claudication Yes No
Ezeonyeji [13] 2011 31 4.6 (2.8) – – –
Scalp tenderness Yes No
Ezeonyeji [13] 2011 27 4.0 (2.9) – – –
GCA
Cranial vs. non-cranial Cranial Non–cranial
Desmet [28] 1990 21 1.2 (1.6) 13 3.1 (4.0) <0.05
Brack [31] 1999 74 11.1 (7.5) 74 34.7 (34.2) <0.001
Liozon [11] 2003 130 10.0 (8.2) 21 17.6 (7.9) 0.003
Gonzalez-Gay [44] 2005 199 9.8 (10.8) 11 20.2 (17.6) 0.003
Ezeonyeji [13] 2011 – – 21 5.4 (3.5) –
Czihal [41] 2012 51 6.5 (6.6) 59 28.7 (25.1) <0.01
GCA with PMR GCA GCA & PMR
Myklebust [30] 1996 39 6.4 (7.2) 15 8.1 (10.7) –
Gonzalez-Gay [44] 2005 144 8.3 (10.0) 96 13.4 (12.2) <0.001
Biopsy result Positive Negative
Duhaut [32] 1999 207 6.9 (50.2) 85 4.7 (26.0) –
Gonzalez-Gay [47] 2001 161 7 (1.7) 29 8 (4.0) 0.6
Demographic
Age <69 years ≥70 years
Lopez-Diaz [49] 2008 46 13.2 (12.8) 227 9.4 (10.2) 0.03
Location Rural Urban
Gonzalez-Gay [48] 2003 132 9.9 (11.7) 78 11.1 (10.9) 0.23
Sex Men Women
Gonzalez-Gay [48] 2003 97 9.7 (12.6) 113 11.0 (10.4) 0.20
aStatistical comparison of groups from original article
PMR polymyalgia rheumatica
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There may also be more specific reasons for delay, for
example, varying test availability (i.e. ultrasonography) due
to different service provision by geographical region or
local funding allocation. Linked to variations in the point
at which delay occurs, the terminology of delay should
also be reconsidered. Future research should make the
distinction between ‘consultation delay’ (the period from
symptom onset to receiving a consultation) and ‘diagnos-
tic delay’ (the time between first consultation and final
diagnosis). This acknowledges that clinical diagnosis is not
possible until the patient initiates contact with a health
professional. Research has demonstrated that through dis-
ease awareness programmes it is possible to reduce delay
at any stage of the disease pathway [19] and thus the im-
portance of our review exists in determining an evidence-
based baseline level of delay in GCA diagnosis that future
studies must attempt to reduce.
The strength of this systematic review and meta-
analysis is that it provides the first systematic approach
to pool diagnostic delay of GCA in the world literature.
We have also collated those articles that have examined
delay related to specific GCA characteristics to identify
barriers to receiving a prompt diagnosis.
The primary limitation of our research is that hetero-
geneity may have been introduced due to the way in
which delay data were recorded. In each article, delay
was a secondary outcome and little (or no) information
was provided on how this information was obtained, for
example, as part of routinely recorded clinical care (ei-
ther contemporaneously or retrospectively) or whether
patients were asked as part of the study protocol. How-
ever, as the majority of articles did define delay through
the same phrasing (the time between GCA symptom on-
set and GCA diagnosis), the manner in which this was
collected may be less important. Furthermore, though
more detail on the mechanisms of delayed GCA diagno-
sis would be of great benefit, from the perspective of the
patient or clinician, this is the best data that we pres-
ently have to understand the current issue of delay and
therefore provides our best estimate to date.
Several articles report diagnostic delay data which is
skewed. Though this may be considered as an influence
on our final pooled values, standard meta-analytic
methods assume normality in the distribution of the
means (but not the raw data) and they are valid when
sample sizes within individual studies are sufficient to
enable the central limit theorem to hold. Related to the
variance observed within articles, our meta-analyses re-
ported high levels of heterogeneity. Though this is to be
expected due to the high level of variance of delay
Fig. 3 Meta-analysis comparing delay in diagnosis between GCA with cranial or non-cranial characteristics
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reported, the study populations used in the meta-
analyses were similar in the characteristics of age, pro-
portion of females, two-thirds had defined GCA using a
positive temporal artery biopsy (sensitivity analysis
showed no difference in delay) and all but two patient
samples were from secondary care. Despite this, it
should be noted that data included in the meta-analysis
did cover a wide time range (1950–2013), in which dis-
ease awareness and diagnostic methods will have varied.
However, overall, we are confident that our meta-
analysis, using reported mean values, provides the best
estimate available of diagnostic delay in GCA patients.
Conclusions
Despite the reported time-period of diagnostic delay
being considerably varied within some article samples,
on average, patients experience a 9-week delay between
the onset of their symptoms and receiving a diagnosis
of GCA. Even when the patient has a ‘classical’ cranial
presentation, delay remains considerable. In view of the
potentially serious consequences of a missed GCA diag-
nosis, a reduction in diagnostic delay would be beneficial
and could result in overall cost savings for healthcare
systems [53]. Our research provides a new evidence-based
benchmark of diagnostic delay of GCA against which
future efforts to reduce this problem can be measured
and supports the need for improved public awareness
and fast-track diagnostic pathways.
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